Cryosite (ASX:CTE) Ending Cash Position: A$2.54 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:CTE Cryosite Ltd ASX:CTE
48 GF Score
Price A$1.20
GF Value A$0.95
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Cryosite Ending Cash Position?

Cryosite ASX:CTE 48 Ending Cash Position is A$2.54 Mil as of Dec. 2025. GuruFocus rates ASX:CTE with a GF Score™ of 48/100 and a GF Value™ of A$0.95 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Cryosite's Ending Cash Position for the quarter that ended in Dec. 2025 was A$2.54 Mil.

Cryosite's quarterly Ending Cash Position increased from Dec. 2024 (A$4.49 Mil) to Jun. 2025 (A$5.06 Mil) but then declined from Jun. 2025 (A$5.06 Mil) to Dec. 2025 (A$2.54 Mil).

Cryosite's annual Ending Cash Position declined from Jun. 2023 (A$4.73 Mil) to Jun. 2024 (A$4.70 Mil) but then increased from Jun. 2024 (A$4.70 Mil) to Jun. 2025 (A$5.06 Mil).

Cryosite Ending Cash Position Related Terms

Cryosite Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Cryosite's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cryosite Ending Cash Position Chart

Cryosite Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.88 5.34 4.73 4.70 5.06

Cryosite Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.93 4.70 4.49 5.06 2.54
ASX:CTE
48GF Score
Cryosite Ltd ASX:CTE
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cryosite Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Cryosite's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=4.703+0.357
=5.06

Cryosite's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=5.06+-2.522
=2.54

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of A$2.54 Mil mean?
Cryosite (ASX:CTE) has a Ending Cash Position of A$2.54 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Cryosite and its competitors.
Is Cryosite's Ending Cash Position too high?
Cryosite's current Ending Cash Position is A$2.54 Mil. Overall, Cryosite has a GF Score™ of 48/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cryosite's Ending Cash Position compare to TMO and DHR?
Cryosite's Ending Cash Position of A$2.54 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Diagnostics & Research company?
A good Ending Cash Position depends on the Medical Diagnostics & Research industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Cryosite and its competitors. Cryosite's current Ending Cash Position is A$2.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryosite stock overvalued right now?
Based on GuruFocus' analysis, Cryosite (ASX:CTE) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.95, compared to a current price of A$1.20 — trading 26.3% above its estimated fair value. The current Ending Cash Position is A$2.54 Mil. Cryosite's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Cryosite (ASX:CTE), the current Ending Cash Position is A$2.54 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cryosite (ASX:CTE) Overvalued in 2026?

Based on GuruFocus' analysis, Cryosite stock appears to be overvalued. The current stock price of A$1.20 is trading 26.3% above its estimated GF Value™ of A$0.95. GuruFocus considers Cryosite to be Modestly Overvalued.

Key valuation signals for ASX:CTE:

  • Ending Cash Position: A$2.54 Mil
  • GF Value™: A$0.95 vs. price of A$1.20 (26.3% above fair value)
  • GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the ASX:CTE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cryosite Business Description

Address 13a Ferndell Street, South Granville, Sydney, NSW, AUS, 2142
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
48GF Score

Get the complete analysis for ASX:CTE

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.20
Price
A$0.95
GF Value